Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter

Clin Cancer Res. 2014 May 1;20(9):2498-9. doi: 10.1158/1078-0432.CCR-13-2349.

Authors

Mathias Bernhardt¹, Elias Orouji, Lionel Larribere, Christoffer Gebhardt, Jochen Utikal

Affiliation

¹ Authors' Affiliations: Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.

PMID: 24789037
DOI: 10.1158/1078-0432.CCR-13-2349

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm*
Fatal Outcome
Humans
Indoles / pharmacology
Indoles / therapeutic use*
Male
Melanoma / drug therapy*
Melanoma / genetics
Melanoma / metabolism
Melanoma / pathology*
Neoplasm Staging
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Pyridones / pharmacology
Pyridones / therapeutic use
Pyrimidinones / pharmacology
Pyrimidinones / therapeutic use
Sulfonamides / pharmacology
Sulfonamides / therapeutic use*
Treatment Outcome
Vemurafenib

Substances

Antineoplastic Agents
Indoles
Protein Kinase Inhibitors
Pyridones
Pyrimidinones
Sulfonamides
Vemurafenib
trametinib
Proto-Oncogene Proteins B-raf